The FDA approved Wilserdly with everolimus for advanced ESR1-mutated breast cancer after a trial showed slower progression; survival data are not yet mature.

The US Food and Drug Administration on 16 November approved Wilserdly (giredestrant), an oral pill from Roche's Genentech unit, to be taken with the existing drug everolimus by adults with ER-positive, HER2-negative, ESR1-mutated breast cancer that is locally advanced or has spread. It is meant for patients whose cancer came back during or after hormone-based therapy following surgery, or worsened on at least one hormone-based treatment for metastatic disease. The decision rests on evERA, a randomised, open-label trial of 373 adults, 207 of whom had the ESR1 mutation. In that group, the median time before the cancer progressed was 10 months with giredestrant plus everolimus, against 5.5 months with standard hormone therapy plus everolimus, a 62% lower risk of progression or death.

Giredestrant belongs to a class called oral selective estrogen receptor degraders, which block and break down the receptor that fuels most breast cancers. ESR1 mutations often appear after years of hormone treatment and help tumours resist it; the same class already includes elacestrant and imlunestrant. Tumours shrank in 27% of patients on the new combination, compared with 14% on standard therapy. The results have clear limits. Overall survival data were still immature, so it is not yet known whether patients live longer. The trial was open-label and funded by Roche. Side effects included mouth sores, rash, fatigue, diarrhoea and lung inflammation, and the label warns of a slow heart rate and harm to an unborn baby. Erica Mayer of Dana-Farber, the study's lead investigator, called it an important new option.

For readers, the approval concerns a specific group: people with advanced hormone-receptor-positive breast cancer whose tumours carry an ESR1 mutation, confirmed by an FDA-authorised blood test, FoundationOne Liquid CDx. It is not a treatment for early breast cancer, and the decision applies to the United States; the FDA reviewed it alongside Health Canada and Israel's health ministry through Project Orbis, and other regulators will decide separately. Patients should not stop or switch their current medicines on their own. Anyone who thinks this option may be relevant should ask their oncologist whether mutation testing makes sense in their case. Health authorities, including the WHO, stress that knowing the signs of breast cancer and following national screening advice remain the best ways to catch the disease early.